Articles related to Pediatric Infectious Diseases

Analysis of 900 fungal isolates from pediatric invasive fungal infections found low overall resistance rates to azoles and echinocandins across most species. Isavuconazole demonstrated activity comparable to established triazoles against many clinically important molds and yeasts.

The FDA expanded approval of Capvaxive, a pneumococcal 21-valent conjugate vaccine, to children and adolescents aged 2 to 17 years with at least one chronic medical condition increasing pneumococcal disease risk, based on STRIDE-13 trial data showing noninferiority to PPSV23 across 12 shared serotypes and statistically significantly higher OPA GMTs for 9 serotypes unique to Capvaxive.

Neonatal sepsis affects an estimated 22 per 1,000 live births globally and carries significant morbidity risk, with PA-authored CME examining risk stratification, diagnostic sequencing, and antimicrobial stewardship for the practicing provider.

A retrospective quasi-experimental study at St. Jude Children’s Research Hospital found that discontinuing empiric antibiotics within 72 hours of febrile neutropenia onset in clinically stable pediatric haploidentical HCT recipients reduced antibiotic exposure by a median of 8 days without significant differences in bloodstream infection, ICU admission, or mortality.

The 2026 Surviving Sepsis Campaign pediatric guidelines issued 61 recommendations covering infection recognition, hemodynamics, ventilation, and long-term follow-up for children with sepsis or septic shock.

Updated pediatric CAP guidelines refine the evaluation and management of parapneumonic effusion, prioritizing less invasive imaging and procedural strategies while aiming to reduce potential harm.